12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Company News  |  Other News

Cellerant other news

HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded an additional $36.4 million to Cellerant to continue development of CLT-008 for acute radiation syndrome (ARS). The funding part of a 2010 BARDA five-year contract...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >